Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease
Journal of Clinical Oncology · 2023
DOI: 10.1200/jco.22.01203 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, 2023. Verfasst von Mary Eapen und 24 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Graft vs Host Disease, Leukemia, Myeloid, Acute, Anemia, Sickle Cell. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIAID NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE To report the incidence and risk factors for secondary neoplasm after transplantation for sickle cell disease. METHODS Included are 1,096 transplants for sickle cell disease between 1991 and 2016. There were 22 secondary neoplasms. Types included leukemia/myelodysplastic syndrome (MDS; n = 15) and solid tumor (n = 7). Fine-Gray regression models examined for risk factors for leukemia/MDS and any secondary neoplasm. RESULTS The 10-year incidence of leukemia/MDS was 1.7% (95% CI, 0.90 to 2.9) and of any secondary neoplasm was 2.4% (95% CI, 1.4 to 3.8). After adjusting for other risk factors, risks for leukemia/MDS (hazard ratio, 22.69; 95% CI, 4.34 to 118.66; P = .0002) or any secondary neoplasm (hazard ratio, 7.78; 95% CI, 2.20 to 27.53; P = .0015) were higher with low-intensity (nonmyeloablative) regimens compared with more intense regimens. All low-intensity regimens included total-body irradiation (TBI 300 or 400 cGy with alemtuzumab, TBI 300 or 400 cGy with cyclophosphamide, TBI 200, 300, or 400 cGy with cyclophosphamide and fludarabine, or TBI 200 cGy with fludarabine). None of the patients receiving myeloablative and only 23% of those receiving reduced-intensity regimens received TBI. CONCLUSION Low-intensity regimens rely on tolerance induction and establishment of mixed-donor chimerism. Persistence of host cells exposed to low-dose radiation triggering myeloid malignancy is one plausible etiology. Pre-existing myeloid mutations and prior inflammation may also contribute but could not be studied using our data source. Choosing conditioning regimens likely to result in full-donor chimerism may in part mitigate the higher risk for leukemia/MDS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.
- Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI.
- Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA.
- University of California San Francisco Benioff Children's Hospital, Oakland, CA.
- Dana-Farber Cancer Center, Harvard Medical School, Boston, MA.
- Ann and Robert H. Lurie Children's Hospital, Chicago, IL.
ORCID-Profile: Mary Eapen, Ruta Brazauskas, David A Williams, Kira Bona, Victoria H Coleman-Cowger, Courtney D Fitzhugh, Julie Kanter, Donald B Kohn, Lakshmanan Krishnamurti, Wendy B London, Michael A Pulsipher, Alexis A Thompson, Edmund K Waller, Ted Wun, Mary M Horowitz
Förderung
- NHLBI NIH HHS
- NIAID NIH HHS
- NCI NIH HHS
Zitieren
APA
Eapen, M., Brazauskas, R., Williams, D. A., Walters, M. C., St Martin, A., Jacobs, B. L., Antin, J. H., Bona, K., Chaudhury, S., Coleman-Cowger, V. H., DiFronzo, N. L., Esrick, E. B., Field, J. J., Fitzhugh, C. D., Kanter, J., Kapoor, N., Kohn, D. B., Krishnamurti, L., London, W. B., …, & Horowitz, M. M. (2023). Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease. Journal of Clinical Oncology. https://doi.org/10.1200/jco.22.01203
Vancouver
Eapen M, Brazauskas R, Williams DA, Walters MC, St Martin A, Jacobs BL, et al. Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease. Journal of Clinical Oncology. 2023. doi:10.1200/jco.22.01203
BibTeX
@article{Eapen2023,
author = {Eapen, Mary and Brazauskas, Ruta and Williams, David A and Walters, Mark C and St Martin, Andrew and Jacobs, Benjamin L and Antin, Joseph H and Bona, Kira and Chaudhury, Sonali and Coleman-Cowger, Victoria H and DiFronzo, Nancy L and Esrick, Erica B and Field, Joshua J and Fitzhugh, Courtney D and Kanter, Julie and Kapoor, Neena and Kohn, Donald B and Krishnamurti, Lakshmanan and London, Wendy B and Pulsipher, Michael A and Talib, Sohel and Thompson, Alexis A and Waller, Edmund K and Wun, Ted and Horowitz, Mary M},
title = {Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease},
journal = {Journal of Clinical Oncology},
year = {2023},
doi = {10.1200/jco.22.01203}
}
EUVIMED